Pancreatic cancer vaccine shows early success
A preliminary trial has shown that an experimental vaccine targeting a key genetic mutation in pancreatic cancer is both effective and safe. It successfully stimulated a long-term immune response in 90% of participants, and no cases of pancreatic cancer or development of high-risk lesions were recorded during a follow-up period of 16.5 months. The vaccine, called "M.Keras-Face," is used for disease prevention by destroying cells carrying K-RAS mutations before they develop into cancer. It is the first similar vaccine proven to be safe and to elicit an immune response directly. These results suggest the potential of using the vaccine for pancreatic cancer prevention, although further studies are needed to confirm its efficacy in ultimately preventing the disease.
Notice: This Is an AI-Generated Summary
Comments (0)